Goldman Sachs Initiates Coverage of Apellis Pharmaceuticals (APLS) with Buy Recommendation
Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) – Epidarex
Is There a Regulatory Strategy Lesson in the FDA's Recent pegcetacoplan (SYVFORE) approval for Geographic Atrophy : r/RegulatoryClinWriting
Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union | APLS Stock News
APLS Stock (NASDAQ:APLS) Recovers, Will it Sustain at $50?
APLS Stock News: Investors with Significant Losses in
Apellis cuts quarter of staff amid focus on eye drug
Apellis Reports Results of Pegcetacoplan in P-III (DERBY and OAKS) Studies for Geographic Atrophy (GA)
Trial of Pegcetacoplan in Recently Diagnosed ALS Patients Opens
Apellis Pharmaceuticals, Inc. Aktie News
APLS INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit | Business Wire
Insider Sell: Pascal Deschatelets Sells 12,000 Shares of Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals Expands Leadership Team, Appoints Adam Townsend as Chief Commercial Officer - Apellis Pharmaceuticals, Inc.
Apellis Expects to Receive a Negative Vote for its European Application for Pegcetacoplan for GA
Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Apellis Pharma (@ApellisPharma) / X
Apellis Pharma Price Prediction: Will APLS Stock, Take Support?
Apellis stops dosing of pegcetacoplan in ALS trial after data review | No safety concerns, but early results don't support continuing study | ALS News Today
Pegcetacoplan (APL-2) by Apellis Pharmaceuticals expected
US FDA approves Apellis's geographic atrophy therapy Syfovre
%20copy_1661347616.jpg "Apellis Announces 24-Month Results in Phase 3 Studies Examining Pegcetacoplan in Geographic Atrophy (GA)")
Apellis Announces 24-Month Results in Phase 3 Studies Examining Pegcetacoplan in Geographic Atrophy (GA)
Apellis Pharma (@ApellisPharma) / X
Apellis Pharmaceuticals on LinkedIn: Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the…
Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration - Apellis Pharmaceuticals, Inc.
Apellis expands R&D collaboration with Affilogic to develop targeted complement therapies for delivery into the brain - Atlanpole Biotherapies : Atlanpole Biotherapies
